Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
Send Cancel

PetMedix and Zoetis to collaborate on antibody therapies
"Collaborating with PetMedix complements our own research and development activities, and we are pleased to be working with them to explore areas of unmet clinical needs in pets" - Robert J. Polzer, Zoetis.

Firms will use transgenic platforms for antibody discovery.

PetMedix has joined forces with Zoetis to develop new species-specific
animal monoclonal antibody therapies (mAbs) using its proprietary transgenic platforms.

Through the partnership, PetMedix will carry out discovery activities against a number of key targets, while Zoetis will have exclusive rights to develop and bring these therapies to market.

Having already brought three novel mAbs to market, Zoetis is a leader in companion animal antibody therapeutics, including fully species-specific antibodies.

PetMedix chief executive Dr Tom Weaver commented: "We are excited to be partnering with Zoetis. Bringing together our unique pet antibody discovery engine with their proven ability to not just develop antibodies, but also make them a commercial success, is set to be a winning combination."

While many technologies have been used to develop human therapeutic antibodies, 40 years of research highlights the benefits of antibodies which are 100 per cent species-matched to the patient.

PetMedix is looking to build on this success for companion animals. Its Ky9™ and Felyne™ platforms were developed in the same way as the leading human transgenic platforms. The collaboration also marks the third publicly-announced deal Zoetis has made with companies using transgenic platforms for antibody discovery.

Zoetis executive vice president and president Robert J. Polzer, said: "At Zoetis, we are committed to continuing our leadership to develop and discover new therapeutic antibodies that can help pets live longer, healthier lives. Collaborating with PetMedix complements our own research and development activities, and we are pleased to be working with them to explore areas of unmet clinical needs in pets."

Image (C) PetMedix.

Become a member or log in to add this story to your CPD history

VET Festival returns for 2022

News Story 1
 VET Festival, the unique CPD opportunity, is returning for 2022, running from 20 to 21 May.

The outdoor event, held at Loseley Park in Guildford, will feature 17 education streams, with a dedicated stream covering veterinary wellness, leadership and management topics. The festival will feature veterinary speakers from around the world, with the opportunity to collect 14 hours of CPD across the two-day event.

Alongside veterinary education, VET Festival will also offer wellbeing activities such as yoga and mindfulness activities, with the popular VETFest Live Party Night making a return for 2022.

Tickets available here.  

Click here for more...
News Shorts
Free webinar on rearing better heifers

A free webinar is being held by Volac to help dairy farmers rear better heifers. Marking the Agriculture and Horticulture Development Board's (AHDB) 'Great British Calf Week', the webinar is scheduled to take place at 12.15pm - 1.45pm on Thursday 3 February 2022.

Focusing on the management input needed to produce better heifers, the webinar will explore practical tips for better calf rearing, sustainable growth through effective calf nutrition, and the importance of sustainable ingredients in calf milk formulas.

Anyone interested in attending can register here.